Overview

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study

Status:
Completed

Trial end date:
2018-04-26

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 18 to 50 years.

Phase:

Phase 3

Details

Lead Sponsor:

Estetra

Collaborator:

PRA Health Sciences

Treatments:

Contraceptive Agents
Contraceptives, Oral
Drospirenone